Progenika Biopharma

Progenika Biopharma Grifols.jpg

Contact information

Progenika Biopharma, SA
Sergio Escorza, Director de Alianzas Estratégicas Internacionales
Parque Tecnológico de Bizkaia
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • In vitro diagnostics
    • Therapeutic areas
      • Analgesia & Pain
      • Dermatology
      • Cardiovascular diseases and circulatory system
      • Genetic and rare diseases
      • Infectious diseases
      • Inflammatory diseases
      • Immunology
      • Ophtalmology and optometry
      • Oncology
      • Blood and lymphatic system
      • Digestive system and hepatology
      • Kidney and genitourinary system
      • Central nervous system
      • Metabolic disorders / Endocrinology
  • B. Agrifood Biotechnology
    • Agriculture / veterinary / environmental
      • Other enhancement techniques (molecular marker..)
      • Animal health / Veterinary
  • C. Industrial Biotechnology
    • Manufacture of biotech equipment
  • D. Services
    • R&D services
      • Bioinformatics
      • Biotechnolgy kits
      • Genomics
      • Metabolomics
      • Proteomics
    • Professional services
      • Consultancy

Progenika´s mission is to improve healthcare through the development, validation and commercialization of products that allow personalization of treatment for complex diseases: in vitro tests for their prevention, diagnosis and prognosis; prediction of response to drugs; and monitoring of the effectiveness of biologic therapies.

Products and services

Areas of expertise and interest for Progenika Group companies include:

  • Genotyping: Testing based on SNPs is applicable to a broad spectrum of studies, such as the identification of diseases and etiological research, gene association, mutational analyses, or associations between disease and gain/loss of chromosomal regions.
  • Massive sequencing: de novo and re-sequencing technologies allow gathering significant gene functional information, offering a high capacity and data quality unattainable by traditional sequencing.
  • Analyses of gene expression: our platforms make it possible to analyze simultaneously, in a quantitative and reproducible way, the expression levels of thousands of genes involved in a particular physiological process. Projects aimed at a restricted number of candidate genes and/or validation of expression markers is also possible.
  • Non-coding RNA: the large number of genes regulated by microRNAs makes the analysis of this kind of molecules particularly interesting to identify those that are associated with different pathologies.
  • Gene regulation: there are several technological options for the analysis of regulatory mechanisms, from massive sequencing studies applied to analysis of methylation to specific studies using microarrays.
  • Production of solid and liquid microarrays and immunoassays: tests for the detection of proteomic and genomic biomarkers can be implemented in different formats, such as ELISAs, chips, or liquid arrays based on suspended microspheres or microparticles.tion sequencing; or solid array, liquid array and immunoassay development